aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational Webinar
- Poster Presentations to Explore Potential of Augmenting Resokine Pathway in Severe, Rare Pulmonary Diseases with an Immune or Fibrotic Component -
- Conference Call and Webcast Featuring Guest Speaker Dr.
In conjunction with the ATS presentations,
Details of the ATS poster sessions are below:
Fibrosis: Mediators and Modulators -
- Title: Resokine Modulates Immune Cell Infiltration into the Lung and Provides Therapeutic Activity in a Bleomycin-Induced Lung Fibrosis Model
- Author and Presenter:
Kathy Ogilvie, PhD, Director, Physiology, aTyr Pharma
- Supporting Authors: Do M., Chiang K., Adams R., Crampton S., Nangle L., Cubitt A., McKew J., Ashlock M., Mendlein J.
- Poster Viewing:
11:15 a.m.– 1:00 p.m. ET
- Location: Area A, Hall B-C (
Middle Building, Lower Level), Walter E. Washington Convention Center
Immune Pathways in Acute Lung Injury and Fibrosis -
- Title: The Resokine Pathway Is Implicated in the Pathology of Interstitial Lung Disease
- Author and Presenter:
Leslie A. Nangle, PhD, Director, Discovery Biology, aTyr Pharma
- Supporting Authors: Tong Y., Mertsching E., Crampton S., Adams R., Chiang K., Ogilvie K., Schimmel P., McKew J., King D., Mendlein J.
- Poster Viewing:
9:15 a.m.– 9:45 a.m. ET
- Poster Discussion: 9:45 a.m. –
11:15 a.m. ET
Room 206( South Building, Level 2), Walter E. Washington Convention Center
The presentations provide early preclinical support for the development of the iMod.Fc program for the treatment of patients with severe, rare pulmonary diseases characterized by an immune or fibrotic component. aTyr plans to initiate its first clinical trial for the iMod.Fc program in the second half of the year.
Conference Call and Webcast Details
To access the call, please dial 844-358-9116 (domestic) or 209-905-5951 (international) and ask to join the
About the iMod.Fc Program
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act. Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the potential and potential therapeutic benefits of iMod.Fc, the ability of the Company to successfully advance its pipeline or product candidates, undertake certain development activities (such as clinical trial enrollment and the conduct of clinical trials) and accomplish certain development goals and the timing of such activities and development goals, the timing of initiation of additional clinical trials, the scope and strength of our intellectual property portfolio, our ability to receive regulatory approvals for, and commercialize, our product candidates and of reporting results from our clinical trials reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the discovery, development and regulation of our Physiocrine-based product candidates, as well as those set forth in our most recent Annual Report on Form 10-K for the year ended
Mark JohnsonSr. Director, Investor Relations email@example.com 858-223-1163